Immunome Inc. Company Profile
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:37 AM ET
Immunome at a glance
Immunome Inc. (NASDAQ: IMNM) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Bothell, WA. Immunome is led by Dr. Clay B. Siegall Ph.D. and employs about 247 people. The company's shares have traded publicly since 2020.
At a market capitalization of $2.28 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001472012, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Immunome do?
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Business description based on the company's public filings.
Company information
- Legal name
- Immunome Inc.
- Ticker
- NASDAQ: IMNM
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Clay B. Siegall Ph.D.
- Employees
- 247
- Headquarters
- 18702 North Creek Parkway, Bothell, WA, United States
- Phone
- 425 939 7410
- Website
- immunome.com
- IPO year
- 2020
- Market cap
- $2.28B
- SEC CIK
- 0001472012
- Latest annual report
- 10-K · Mar 3, 2026
Companies similar to Immunome
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HRMYHarmony Biosciences Holdings Inc. | 39.00 | -0.86% | $2.27B | vs IMNM |
| NRIXNurix Therapeutics Inc. | 22.13 | -2.64% | $2.30B | vs IMNM |
| BHCBausch Health Companies Inc. | 6.16 | 0.00% | $2.30B | vs IMNM |
| IRONDisc Medicine Inc. | 60.08 | -1.81% | $2.31B | vs IMNM |
| PBHPrestige Consumer Healthcare Inc. | 47.30 | -0.58% | $2.24B | vs IMNM |
| SLSSELLAS Life Sciences Group Inc. | 11.03 | -2.47% | $2.23B | vs IMNM |
| PHVSPharvaris N.V. | 31.23 | -1.42% | $2.19B | vs IMNM |
| LQDALiquidia Corporation | 26.55 | -0.49% | $2.38B | vs IMNM |